Newomics, Inc.

📍 Berkeley, United States👥 9 employees💰 Last funded Aug 2018
Biotechnology Research🌐 newomics.com
Website LinkedIn
Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Newomics, Inc.?
Newomics, Inc. has 1 investors on record on gritt.io.
When did Newomics, Inc. last raise funding?
The most recent investment in Newomics, Inc. recorded on gritt.io was in August 2018.
What industry is Newomics, Inc. in?
Newomics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Newomics, Inc. based?
Newomics, Inc. is headquartered in Berkeley, United States.